Skip to main content

Table 3 Cox proportional hazards regression analysis of clinical relapse

From: Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B

  Clinical Relapse (n = 41)
Univariable Multivariablea
HR 95% CI P HR 95% CI P
End of treatment
 Age 1.069 1.025–1.114 0.002 1.062 1.016–1.110 0.007
 Age > 35 y 2.647 1.324–5.291 0.006    
 Sex 1.44 0.662–3.133 0.358    
 First-line NA therapy b 1.233 0.667–2.281 0.504    
 Consolidation duration 0.996 0.980–1.011 0.596    
 Consolidation duration 3 > y 0.777 0.401–1.508 0.456    
 ALT × ULN 0.861 0.331–2.241 0.759    
 HBsAg log10 IU/ml 1.1725 1.177–2.529 0.005 2.086 1.286–3.385 0.003
 HBsAg >200IUmL (vs ≤ 200IUmL) 3.697 1.447–9.444 0.006    
 HBV DNA level elevation log10 IU/ml 1.000 1.000–1.000 0.030 1.000 1.000–1.000 0.045
 HBV DNA level elevation > 20000 IU/ml (vs ≤ 20000 IU/ml) 2.531 1.179–5.435 0.017    
 sST2 log10 pg/mL 2.816 0.731–10.845 0.132    
 sST2 > 3.7 log10 pg/mL(vs ≤ 3.7 log10 pg/mL) 1.718 0.841–3.508 0.137    
 12 W sST2 log10 pg/mL 4.655 2.345–9.243 < 0.001 4.403 2.169–8.937 < 0.001
Start of treatment
 HBeAg 0.726 0.384–1.375 0.326    
 ALT × ULN 0.986 0.935–1.019 0.403    
 HBV DNA log10 IU/ml 0.745 0.792–1.385 0.745    
  1. Abbreviations: ALT Alanine aminotransferase, CI Confidence interval, HBeAg Hepatitis B virus envelope antigen, HBsAg Hepatitis B virus surface antigen, HBV Hepatitis B virus, HR Hazard ratio, NA Nucleos(t)ide analogue, ULN Upper limit of normal
  2. aAdjusted for start-of-treatment HBeAg status and factors that were statistically different between HBeAg-positive and HBeAg-negative patients (age and consolidation therapy duration)
  3. bEntecavir